GPX Medical AB (publ) was founded in 2016 as a wholly owned subsidiary of Gasporox AB (publ) and in 2017 the company's strategic technical partner Norsk Elektro Optikk AS became a partner. Gasporox is today a global player that has successfully commercialized its unique gas measurement technology, which is used, among other things, for quality assurance of packaging and product sustainability in the pharmaceutical, food and beverage industries. GPX Medical was formed as a separate subsidiary to focus on developing medical technology equipment based on Gasporox proven gas measurement technology to, among other things, contribute to better care of premature babies. Since its inception, GPX Medical has laid a solid foundation for the development of the NEOLA® lung monitoring equipment, which the Board believes has great potential in the global market for intensive care equipment for premature babies with various forms of lung disease and breathing difficulties.
In July 2020, Gasporox decided to divide its shares (owned 53,5% of GPX Medical) in GPX Medical to Gasporox shareholders. The record date for this is 26th of August 2020. As of 27th of August 2020, GPX Medical is no longer a subsidiary of Gasporox but the companies will continue the strong technical cooperation that has been developed over the years.
The board of GPX Medical has decided to list the company on Nasdaq First North with listing date 2nd of October 2020. More information on the GPX Medical website.
Caring for the most fragile patients
Next generation neonatal care
Never before have we had so many babies born too soon. More than one out of ten new-born babies need neonatal care. Pulmonary complications are often the primary reason since the lungs of these babies are not yet fully developed. Today the lung status is mainly assessed by routine X-ray imaging and invasive blood sampling, despite the increased risks of long-term complications from ionizing radiation, blood loss, infection and pain.
We believe preterm born babies deserves a better start in life. That’s why we developed NEOLA® to monitor the lungs of these babies continuously. Based on an advanced spectroscopic technology for measurements of gas concentrations cavities, the device detects and instantly warns for possibly life-threatening pulmonary complications. Fast detection means early treatment by the neonatologist and better care for the baby.
NEOLA® - How does it work?
Many preterm born infants suffer from pulmonary complications for which an early detection is critical for good care. GPX Medical’s NEOLA® continuously measures lung volume and oxygen content in the lungs for an instant detection of complications such as atelectasis and pneumothorax, if the airways are obstructed or if the tracheal tube is misplaced.
• Near-infrared light is sent through the torso. A small portion is absorbed by water vapor and oxygen gas molecules in the lungs.
• The detector probe detects some of the light that travelled through the tissue.
• The signal shows how much of the light that has been absorbed by the gas molecules.
• The light is low power, eyesafe and does not induce heating.
• The small and light-weight emitter and detector probes are positioned on the skin.
• Once positioned, NEOLA® will register small changes related
to lung volume and oxygen content.
• The probes are easily removed and re-positioned.
New tool for sinus diagnostics is needed
About 20% of all prescribed antibiotics relate to sinusitis. 75% is predicted to be over-prescription.
Sinusitis is a common and painful disease. About 20% of all prescribed antibiotics globally relate to sinusitis. Of this, it is predicted that 75% is prescribed even though the condition is caused by virus. There is a great need to easily and accurately make a correct diagnosis when patients experience problems with their sinuses, already at the primary care centers. The current methods are often inaccurate or require expensive resources.
The paranasal sinuses are cavities within the scull, which are ventilated through the nose. With GPX Medical technology it is possible to easily measure the amount of gas and the gas composition inside the sinus and gain clinically important information already at the primary care centers.
The method is easy and quick and the result is presented without delay. As the technique does not involve ionizing radiation of the sinuses in the skull it is very safe for the patient. It also means that the healthcare sector can reduce costly and time-consuming investigations as well as decrease prescription of antibiotics.
The feasibility of the technology has been shown in a clinical pilot study where the correlation between assessment of the openness of the sinuses based on CT scan and the GASMAS* method was shown**. The market opportunity for a diagnostic tool for sinusitis is currently under investigation.
*gas in scattering media absorption spectroscopy (GASMAS)
**Non-invasive diagnostics of the maxillary and frontal sinuses based on diode laser gas spectroscopy. Lewander M, Lindberg S, Svensson T, Siemund R, Svanberg K, Svanberg S. Rhinology. 2012 Mar;50(1):26-32.